Expand Smarter in the Cell and Gene Therapy Market – With This 2025–2034 Forecast Report

Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts

How has the cell and gene therapy market size changed in recent years, and what is the outlook ahead?
The cell and gene therapy market size has grown exponentially in recent years. It will grow from $12.01 billion in 2024 to $15.48 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%. The growth in the historic period can be attributed to an increase in investments in cell and gene therapies, growth in research and development, advances in cancer drug discovery, rise in public-private partnerships, strong economic growth in emerging markets, increased healthcare expenditure, and rising in pharmaceutical R&D expenditure.

The cell and gene therapy market size is expected to see rapid growth in the next few years. It will grow to $29.15 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to the increasing prevalence of cancer and chronic diseases, rising geriatric population, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure. Major trends in the forecast period include focusing on advanced therapies such as chimeric antigen receptor (CAR) T-cell therapy, concentrating on undertaking various research initiatives and attaining funding, carrying out strategic collaborations to integrate advanced technologies, concentrating on developing gene or genome editing tools especially CRISPR, partnering or acquiring competitor companies, increasing the number of pipeline studies to develop cell and gene therapies, and investing in manufacturing facilities expansion.

Download Your Free Sample PDF:
Cell And Gene Therapy Market Growth, Drivers Report 2025

What are the top economic and technological drivers pushing cell and gene therapy market growth?
Steady investment and consolidation in cell and gene therapies contributed to the growth of the cell and gene therapy (CGT) market. After recognizing the potential of the CGT market, 16 out of the 20 largest biopharmaceutical companies by revenue, added CGT products to their portfolios. For instance, in 2023, according to the BioIndustry Association (BIA), a UK-based organization representing the life sciences and biotech industry, UK cell and gene therapy companies secured over 55% of the venture capital funding obtained by European firms. Generally, the UK represents around one-third of all European VC investments in life sciences, highlighting the strong position of its cell and gene therapy sector. Steady investment and consolidation in CGT production capacity led to an increase in production capacity and also contributed to the growth of the market. For instance, In October 2024, Purespring Therapeutics a UK based biotechnology company received funding of $105 million to support the development of gene therapies for diseases of the kidney, including a phase 1/2 trial of an experimental treatment for immunoglobulin A nephropathy (IgAN). Purespring utilizes adeno-associated viruses (AAVs) to transport its gene therapies into the body.

How is the cell and gene therapy market segmented by product, application, and end-user?
The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy
2) By Application: Oncology, Neurological Disorders, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:
1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

What are the most notable trends influencing investment in the cell and gene therapy sector?
Chimeric antigen receptor (CAR) T-cell therapy is shaping the cell and gene therapy (CGT) market. (CAR) T-cell therapy is a combination of cell and gene therapy in which T cells are collected from the patient’s blood and are genetically engineered to produce modified receptors at their surface, known as chimeric antigen receptors (CARs). These modified T cells have special structures (receptors) and are reinfused into the patient. Then, the modified receptors of T cells help in targeting the surface antigen of the cancer cell, ultimately resulting in the killing of tumor cells in patients. For instance, in June 2022, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received approval from the United States Food and Drug Administration (US FDA) for CAR T cell therapy Breyanzi for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi is a differentiated CAR T cell therapy made from a patient's own T cells, which are collected and genetically reengineered to become CAR T cells that are then delivered via infusion as a one-time treatment.

Which leading companies are dominating the cell and gene therapy market landscape?
Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Which geographic areas are expected to offer the highest growth opportunities in thecell and gene therapy market?
North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Can Companies Use The Cell and Gene Therapy Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.

Purchase The Report And Get A Swift Delivery:
Cell And Gene Therapy Market Growth, Drivers Report 2025

Need Customized Data On Cell and Gene Therapy Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.

Request Customized Data:
Cell And Gene Therapy Market Growth, Drivers Report 2025

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn